ReviewCurrent opinion in rheumatology2011
IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis.
Review in Current opinion in rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02844023 (Biomarkers in Giant Cells Arteritis), which is not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarkers in Giant Cells Arteritis
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- Aspirin as adjunctive treatment for giant cell arteritis.The Cochrane database of systematic reviews · 2014Pooled it
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Analysis of proinflammatory cytokine responses in Takayasu arteritis.Archives of rheumatology · 2024Article
- A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.International journal of molecular sciences · 2024Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Review
- Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.Cells · 2024Review
- Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.Clinical and experimental medicine · 2022Review
- Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.Annals of the rheumatic diseases · 2022Article
- Pathogenesis of giant cell arteritis with focus on cellular populations.Frontiers in medicine · 2022Review
- Cellular signaling pathways of T cells in giant cell arteritis.Journal of geriatric cardiology : JGC · 2021Article
- Giant Cell Arteritis and Cardiac Comorbidity.Cureus · 2021Review
- Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage.Rheumatology international · 2021Observational
- NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis.The Journal of clinical investigation · 2021Article
- Biologic Therapies for Giant Cell Arteritis.Biologics : targets & therapy · 2021Review
- Glucocorticoid Effects on Tissue Residing Immune Cells in Giant Cell Arteritis: Importance of GM-CSF.Frontiers in medicine · 2021Article
- One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment.Current treatment options in neurology · 2021Review
- Cellular Signaling Pathways in Medium and Large Vessel Vasculitis.Frontiers in immunology · 2020Review
- T Cells in Autoimmunity-Associated Cardiovascular Diseases.Frontiers in immunology · 2020Review
- Mechanism and biomarkers in aortitis--a review.Journal of molecular medicine (Berlin, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewGranuloma formation in giant cell arteritis (GCA) emphasizes the role of adaptive immunity and highlights the role of antigen-specific T cells. Recent data demonstrate that at least two separate lineages of CD4 T cells participate in vascular inflammation, providing an important clue that multiple disease instigators may initiate pathogenic immunity. RECENT FINDING: IFN-γ-producing Th1 cells and IL-17-producing Th17 cells have been implicated in GCA. Patients with biopsy-positive GCA underwent two consecutive temporal artery biopsies, one prior to therapy and one while on corticosteroids. In untreated patients, Th1 and Th17 cells co-existed in the vascular lesions. Following therapy, Th17 cells were essentially lost, whereas Th1 cells persisted almost unaffected. In the peripheral blood of untreated patients Th17 frequencies were increased eight-fold, but normalized with therapy. Blood Th1 cells were doubled in frequency, independent of therapy. Corticosteroids functioned by selectively suppressing IL-1β, IL-6 and IL-23-releasing antigen-presenting cells (APCs), disrupting induction of Th17 cells. SUMMARY: At least two distinct CD4 T-cell subsets promote vascular inflammation in GCA. In early disease, APCs promote differentiation of Th17 as well as Th1 cells. Chronic disease is characterized by persistent Th1-inducing signals, independent of IL-17-mediated inflammation. More than one disease instigator may trigger APCs to induce multiple T-cell lineages. Cocktails of therapies will be needed for appropriate disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.